149 related articles for article (PubMed ID: 36493948)
1. Evaluation in pig of an intestinal administration device for oral peptide delivery.
Berg S; Uggla T; Antonsson M; Nunes SF; Englund M; Rosengren L; Fahraj M; Wu X; Govender R; Söderberg M; Janzén D; Van Zuydam N; Hugerth A; Larsson A; Abrahmsén-Alami S; Abrahamsson B; Davies N; Bergström CAS
J Control Release; 2023 Jan; 353():792-801. PubMed ID: 36493948
[TBL] [Abstract][Full Text] [Related]
2. In Vitro and In Vivo Evaluation of 3D Printed Capsules with Pressure Triggered Release Mechanism for Oral Peptide Delivery.
Berg S; Krause J; Björkbom A; Walter K; Harun S; Granfeldt A; Janzén D; Nunes SF; Antonsson M; Van Zuydam N; Skrtic S; Hugerth A; Weitschies W; Davies N; Abrahamsson B; Bergström CAS
J Pharm Sci; 2021 Jan; 110(1):228-238. PubMed ID: 33212160
[TBL] [Abstract][Full Text] [Related]
3. Systems Biology and Peptide Engineering to Overcome Absorption Barriers for Oral Peptide Delivery: Dosage Form Optimization Case Study Preceding Clinical Translation.
Tyagi P; Patel C; Gibson K; MacDougall F; Pechenov SY; Will S; Revell J; Huang Y; Rosenbaum AI; Balic K; Maharoof U; Grimsby J; Subramony JA
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896196
[TBL] [Abstract][Full Text] [Related]
4. Microcontainers for oral insulin delivery - In vitro studies of permeation enhancement.
Jørgensen JR; Jepsen ML; Nielsen LH; Dufva M; Nielsen HM; Rades T; Boisen A; Müllertz A
Eur J Pharm Biopharm; 2019 Oct; 143():98-105. PubMed ID: 31425857
[TBL] [Abstract][Full Text] [Related]
5. Intestinal Absorption of FITC-Dextrans and Macromolecular Model Drugs in the Rat Intestinal Instillation Model.
Berg S; Suljovic D; Kärrberg L; Englund M; Bönisch H; Karlberg I; Van Zuydam N; Abrahamsson B; Hugerth AM; Davies N; Bergström CAS
Mol Pharm; 2022 Jul; 19(7):2564-2572. PubMed ID: 35642793
[TBL] [Abstract][Full Text] [Related]
6. Experiences and Translatability of
Emeh P; Breitholtz K; Berg S; Vedin C; Englund M; Uggla T; Antonsson M; Nunes F; Hilgendorf C; Bergström CAS; Davies N
Mol Pharm; 2024 Jan; 21(1):313-324. PubMed ID: 38054599
[TBL] [Abstract][Full Text] [Related]
7. Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs.
Raoof AA; Ramtoola Z; McKenna B; Yu RZ; Hardee G; Geary RS
Eur J Pharm Sci; 2002 Nov; 17(3):131-8. PubMed ID: 12393140
[TBL] [Abstract][Full Text] [Related]
8. Formulation strategies to improve the efficacy of intestinal permeation enhancers
Maher S; Brayden DJ
Adv Drug Deliv Rev; 2021 Oct; 177():113925. PubMed ID: 34418495
[TBL] [Abstract][Full Text] [Related]
9. Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage.
Aguirre TAS; Aversa V; Rosa M; Guterres SS; Pohlmann AR; Coulter I; Brayden DJ
J Control Release; 2016 Sep; 238():242-252. PubMed ID: 27480451
[TBL] [Abstract][Full Text] [Related]
10. Intestinal permeation enhancers for oral peptide delivery.
Maher S; Mrsny RJ; Brayden DJ
Adv Drug Deliv Rev; 2016 Nov; 106(Pt B):277-319. PubMed ID: 27320643
[TBL] [Abstract][Full Text] [Related]
11. Interactions of oral permeation enhancers with lipid membranes in simulated intestinal environments.
Larsen NW; Kostrikov S; Hansen MB; Hjørringgaard CU; Larsen NB; Andresen TL; Kristensen K
Int J Pharm; 2024 Apr; 654():123957. PubMed ID: 38430950
[TBL] [Abstract][Full Text] [Related]
12. Considerations in the developability of peptides for oral administration when formulated together with transient permeation enhancers.
Berg S; Edlund H; R F Goundry W; A S Bergström C; Davies NM
Int J Pharm; 2022 Nov; 628():122238. PubMed ID: 36174850
[TBL] [Abstract][Full Text] [Related]
13. Intestinal permeation enhancers to improve oral bioavailability of macromolecules: reasons for low efficacy in humans.
Maher S; Geoghegan C; Brayden DJ
Expert Opin Drug Deliv; 2021 Feb; 18(2):273-300. PubMed ID: 32937089
[TBL] [Abstract][Full Text] [Related]
14.
Tran H; Aihara E; Mohammed FA; Qu H; Riley A; Su Y; Lai X; Huang S; Aburub A; Chen JJH; Vitale OH; Lao Y; Estwick S; Qi Z; ElSayed MEH
Mol Pharm; 2023 Feb; 20(2):929-941. PubMed ID: 36592951
[TBL] [Abstract][Full Text] [Related]
15. Impact of Intestinal Concentration and Colloidal Structure on the Permeation-Enhancing Efficiency of Sodium Caprate in the Rat.
Berg S; Kärrberg L; Suljovic D; Seeliger F; Söderberg M; Perez-Alcazar M; Van Zuydam N; Abrahamsson B; Hugerth AM; Davies N; Bergström CAS
Mol Pharm; 2022 Jan; 19(1):200-212. PubMed ID: 34928160
[TBL] [Abstract][Full Text] [Related]
16. Thiolated polycarbophil/glutathione: defining its potential as a permeation enhancer for oral drug administration in comparison to sodium caprate.
Perera G; Barthelmes J; Vetter A; Krieg C; Uhlschmied C; Bonn GK; Bernkop-Schnürch A
Drug Deliv; 2011 Aug; 18(6):415-23. PubMed ID: 21554106
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys.
Tran H; Dogra M; Huang S; Aihara E; ElSayed M; Aburub A
Int J Pharm; 2024 Jan; 650():123680. PubMed ID: 38070657
[TBL] [Abstract][Full Text] [Related]
18. Identification of a Multi-Component Formulation for Intestinal Delivery of a GLP-1/Glucagon Co-agonist Peptide.
Tran H; Patel PJ; Aburub A; Sperry A; Estwick S; ElSayed MEH; -Mannan AD
Pharm Res; 2022 Oct; 39(10):2555-2567. PubMed ID: 36050547
[TBL] [Abstract][Full Text] [Related]
19. Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels.
Motlekar NA; Srivenugopal KS; Wachtel MS; Youan BB
J Drug Target; 2005 Dec; 13(10):573-83. PubMed ID: 16390818
[TBL] [Abstract][Full Text] [Related]
20. Enhancing Intestinal Absorption of a Model Macromolecule via the Paracellular Pathway using E-Cadherin Peptides.
Dening TJ; Siahaan TJ; Hageman MJ
J Pharm Sci; 2021 May; 110(5):2139-2148. PubMed ID: 33359310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
